BXBozhang Xia

Bozhang Xia

*This is an algorithmically generated author record based on publicly available information.

Bozhang Xia has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Gang Zhang

    CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, No. 11, First North Road, Zhongguancun, Beijing, 100190, P. R. China

    2 shared publications
  • Junge Chen

    Beijing Advanced Innovation Centre for Biomedical Engineering, Key Laboratory for Biomechanics and Mechanobiology of Ministry of Education, School of Engineering Medicine, Beihang University, Beijing, P. R. China

    2 shared publications
  • Xing-Jie Liang

    CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing 100190, PR China

    2 shared publications
  • Zhongbo Hu

    CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, No. 11, First North Road, Zhongguancun, Beijing, 100190, P. R. China

    2 shared publications
  • Fengfei Xu

    CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety CAS Center for Excellence in Nanoscience National Center for Nanoscience and Technology of China No. 11, First North Road, Zhongguancun Beijing 100190 P. R. China

    1 shared publication
  • Fengfei Xu

    CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, No. 11, First North Road, Zhongguancun, Beijing, 100190, P. R. China

    1 shared publication

Latest Publications

  • Open Access

    Site-specific adaptive nanovesicles for oral insulin delivery

    by Bozhang Xia, Fengfei Xu, Junge Chen, Shaobo Shan, Jiuheng Shen, Yuxuan Zhang, Jinjin Wang, Ziran Zhou, Weilun Sun, Yaru Jia, et al.

    Oral delivery of insulin holds great promise for improving patient compliance. However, the harsh gastrointestinal environment, the low permeability of the intestinal epithelium, and hepatic clearance of foreign particles remain key challenges in this area. Here, we report the site-specific adaptive milk-derived nanovesicles (MiNVs) capable of overcoming intestinal and hepatic barriers for oral insulin delivery. These MiNVs could bind natural IgG on their surface, enabling FcRn-mediated transcytosis by evading the lysosomal degradation pathway. Upon reaching the liver, MiNVs responded to the elevated levels of biothiols in the hepatic microenvironment, triggering site-specific insulin release. In type 1 diabetic rats, the oral bioavailability reached 20.4%, which is about 20-fold higher than that of free insulin. Notably, MiNVs showed effective glycemic control over long-term treatment in type 1 diabetic rat and minipig models. By integrating transepithelial transport and liver-specific responsiveness, the site-specific adaptability of MiNVs supports their promise in oral insulin administration.


  • Oral Administration Properties Evaluation of Three Milk‐Derived Extracellular Vesicles Based on Ultracentrifugation Extraction Methods

    by Bozhang Xia, Runjing Hu, Junge Chen, Shaobo Shan, Fengfei Xu, Gang Zhang, Ziran Zhou, Yubo Fan, Zhongbo Hu, Xing‐Jie Liang

    Milk‐derived extracellular vesicles (M‐EVs) are low‐cost, can be prepared in large quantities, and can cross the gastrointestinal barrier for oral administration. However, the composition of milk is complex, and M‐EVs obtained by different extraction methods may affect their oral delivery. Based on this, a new method for extracting M‐EVs based on cryogenic freezing treatment (Cryo‐M‐EVs) is proposed and compared with the previously reported acetic acid treatment (Acid‐M‐EVs) method and the conventional ultracentrifugation method (Ulltr‐M‐EVs). The new method simplifies the pretreatment step and achieves 25‐fold and twofold higher yields than Acid‐M‐EVs and Ulltr‐M‐EVs. And it is interesting to note that Cryo‐M‐EVs and Acid‐M‐EVs have higher cellular uptake efficiency, and Cryo‐M‐EVs present the best transepithelial transport effect. After oral administration of the three M‐EVs extracted by three methods in mice, Cryo‐M‐EVs effectively successfully cross the gastrointestinal barrier and achieve hepatic accumulation, whereas Acid‐M‐EVs and Ultr‐M‐EVs mostly reside in the intestine. The M‐EVs obtained by the three extraction methods show a favorable safety profile at the cellular as well as animal level. Therefore, when M‐EVs obtained by different extraction methods are used for oral drug delivery, their accumulation properties at different sites can be utilized to better deal with different diseases.